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that could undermine the therapeutic index of
any one target. This target-rich environment,
not restricted to mutated oncoproteins, offers
real hope for breakthroughs (or at least
improvements in safety and effectiveness) in
MDS/AML therapy.
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VWF fibers induce thrombosis
during cancer
-----------------------------------------------------------------------------------------------------
Lubor Borsig UNIVERSITY OF ZU¨RICH
In this issue of Blood, Bauer et al1 provide an explanation for the formation of
luminal von Willebrand factor (VWF) ﬁbers observed in cancer patients, which is
initiated through tumor-derived vascular endothelial growth factor-A (VEGF-A).
Platelet aggregation on VWF ﬁbers correlated with a prothrombic state associated
with decreased a disintegrin-like and metalloproteinase with thrombospondin type I
repeats 13 (ADAMTS13) activity in cancer patients.
The association between cancer andthromboembolism was ﬁrst described
by Trousseau more than 100 years ago, when
he made the astute observation that patients
with unexplained thrombosis sometimes had
an occult malignancy.2 The frequently
observed prothrombic state in cancer patients
encompasses a broad variety of complications,
ranging from thrombotic microangiopathy to
deep vein thrombosis. The pathophysiology
of cancer-associated thrombosis is rather
complex, but can be linked to 3 major features:
stasis, vascular injury, and hypercoagulability,
according to the criteria of so-called Virchow
triad.3 Vascular alterations are frequently
observed both in the primary tumor and at
metastatic sites. Increased presence of VWF
in the circulation correlates with endothelial
damage and is used as an indicator for
many pathological situations, including
atherosclerosis, cardiovascular disease, and
cancer.4 VWF forms polymer ﬁbers attached
to the luminal endothelial cells that contribute
to hemostasis-mediating platelet adhesion.
This process is normally controlled by the
plasma metalloprotease ADAMTS13.4
However, VWF ﬁbers also promote
platelet aggregation, which may result in
pathophysiological thrombi formation
and vessel occlusion.5 In the current work,
Bauer et al1 show thatVWFﬁber formation and
the associated platelet aggregation is detected
both in primary tumors of melanoma patients
and in a mouse melanoma model. Although
a clear increase in VWF ﬁber formation was
detected in melanoma patients, there was
a small but signiﬁcant decrease in ADAMTS13
in the tumors. However, enhanced VWF ﬁber
formation in mouse melanoma tumors was
associated with a clearly reduced ADAMTS13
activity. Consequently, intravenous infusion
of recombinant ADAMTS13 signiﬁcantly
reduced luminalﬁber formation inmouse tumors.
What causes endothelial damage during
cancer progression that results in enhanced
thromboembolism is still heavily debated. It
is well known that a variety of procoagulant
factors secreted by tumors such as tissue
factor, thrombin, VEGF, mucins with
selectin binding sites, or tumor necrosis
factor has been shown to be abnormally raised
during cancer and is linked to a prothrombic
state in patients.2,3,6 In addition, these factors
have been shown to trigger thrombosis in
a variety of animal cancer models. In particular,
VEGF is the primary factor inducing
angiogenesis and therefore both physiological
and pathophysiological activation of the
endothelium. Previously, thrombin release
by melanoma cells was shown to induce
endothelial activation associated with VWF
deposition in the vascular lumen.7 Bauer
et al now provide evidence that tumor-derived
VEGF causes endothelial activation, resulting
in enhanced VWF ﬁber deposits in the
vasculature and thereby inducing platelet
aggregation and thrombosis.
There is abundant literature on the use
of heparin and low-molecular-weight
derivatives (LMWH) in cancer patients.
However, there is accumulating evidence
that heparins have cancer inhibitory activity
that goes beyond just anticoagulation.8
Although a rigorous evaluation of heparin or
LMWH on inhibition of cancer progression
is still missing, virtually all animal models
conﬁrmed beneﬁcial effects of heparin or
LMWH on cancer progression.9,10 Because
of the complex biological nature of heparins,
they can affect several potential mechanisms
involved in metastasis, including cell adhesion
through selectins, enzymatic activity of
heparanase, or the activity of growth factors
and cytokines. The study by Bauer et al1 now
provides evidence that LMWH tinzaparin
directly binds to VEGF and thereby reduces
melanoma-induced endothelial activation
associated with VWF ﬁber formation. These
ﬁndings show yet another mechanism for
how heparins may interfere with endothelial
activation and angiogenesis. Long-term
tinzaparin treatment of transgenic mice,
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which spontaneously develop skin melanomas,
signiﬁcantly prolonged survival in these mice. In
particular, reduced VEGF amounts in tumors
and reduced tumor cell proliferation were
affected by tinzaparin treatment, which likely
reﬂect a reduced angiogenesis and cancer
progression.
Taken together, the work of Bauer et al1
provides an important contribution to
our understanding of cancer-induced
prothrombic activity with regard to
endothelial activation and VWF ﬁber
formation in the lumen of cancer-associated
vasculature. Although this work convincingly
shows the relevance of VWF ﬁbers formation
and associated platelet aggregation in primary
tumors of cancer patients, the fundamental
question aswhetherVWFﬁber formation occurs
during metastatic initiation requires further
investigation. Along these lines, the current
ﬁndings show that endothelial activation is
a critical requirement for successful metastasis.
A better understanding of molecular events
leading to VWF ﬁber deposition and subsequent
microthrombus formation could allow the
designing of new therapy approaches.
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Fibronectin: extra domain
brings extra risk?
-----------------------------------------------------------------------------------------------------
Yiming Wang1,2 and Heyu Ni1,2 1ST. MICHAEL’S HOSPITAL; 2CANADIAN BLOOD SERVICES
In this issue of Blood, Prakash et al provide compelling in vitro and in vivo
evidence for a novel role of cellular ﬁbronectin (cFn) containing extra domain A
(Fn-EDA1) in arterial thrombosis.1
F ibronectins (Fn’s) are large dimericmultidomain glycoproteins consisting of
two 230- to 250-kDa monomers linked by
disulﬁde bonds at their C terminus. Each Fn
monomer contains collagen and ﬁbrin binding
sites in the N terminus and an Arg-Gly-Asp
(RGD) integrin binding motif. The alternative
splicing of Fn pre-messenger RNA (pre-
mRNA) generates several Fn variants, which
can be grouped into 2 main categories: plasma
ﬁbronectin (pFn) and cFn. In contrast to pFn,
cFn contains either EDA or EDB or both.2
Fn’s are widely distributed in extracellular
matrix and blood circulation. They are
required for embryogenesis, and are important
for wound healing, infection, and malignant
transformation.3
Using intravital microscopy models, the
roles of both pFn and cFn in thrombosis have
been established in the past decade.4-7 pFn is
synthesized in the hepatocytes and accounts for
almost all of the Fn’s in the normal blood
plasma. The depletion of pFn in mice resulted
in a decrease of thrombus growth and stability.4
It was later found that pFn supports platelet
aggregation and thrombosis only in the
presence of ﬁbrin, and the pFn-ﬁbrin complex
may be a prerequisite for its prothrombotic
activities.5,6 In the absence of ﬁbrin (eg, at the
apical surface of the growing thrombi), pFn
inhibits platelet aggregation, thus preventing
excessive thrombosis and rescuing downstream
blood supply.6 pFn also supports hemostasis
through depositing on the injured vessel wall
Fn-EDA1 interacts with platelet TLR4 to promote thrombosis, possibly through the platelet NF-kB signaling pathway.
Platelet intracellular Fn-EDA1 is packaged from megakaryocytes and possibly also internalized via aIIbb3 integrins,
which are released upon activation from platelet a-granules. Fn-EDA1 may incorporate into fibrin clots, deposit on
vessel wall, and induce NET formation.
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